<p>Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment</p>

Abstract

Purpose: Global evidence-based treatment strategies for chronic obstructive pulmonary disease (COPD) recommend using long-acting bronchodilators (LABDs) as maintenance therapy. However, COPD patients are often undertreated. We examined COPD treatment patterns among Medicare beneficiaries who initiated arformoterol tartrate, a nebulized long-acting beta 2 agonist (LABA), and identified the predictors of initiation. Methods: Using a 100% sample of Medicare administrative data, we identified beneficiaries with a COPD diagnosis (ICD-9 490–492.xx, 494.xx, 496.xx) between 2010 and 2014 who had ≥1 year of continuous enrollment in Parts A, B, and D, and ≥2 COPD-related outpatient visits within 30 days or ≥1 hospitalization(s). After applying inclusion/exclusion criteria, three cohorts were identified: (1) study group beneficiaries who received nebulized arformoterol (n=11,886), (2) a subset of the study group with no LABD use 90 days prior to initiating arformoterol (n=5,542), and (3) control group beneficiaries with no nebulized LABA use (n=220,429). Logistic regression was used to evaluate predictors of arformoterol initiation. Odds ratios (ORs), 95% confidence intervals (CIs), and p values were computed. Results: Among arformoterol users, 47% (n=5,542) had received no LABDs 90 days prior to initiating arformoterol. These beneficiaries were being treated with a nebulized (50%) or inhaled (37%) short-acting bronchodilator or a systemic corticosteroid (46%), and many received antibiotics (37%). Compared to controls, beneficiaries who initiated arformoterol were significantly more likely to have had an exacerbation, a COPD-related hospitalization, and a pulmonologist or respiratory therapist visit prior to initiation (all p <0.05). Beneficiaries with moderate/severe psychiatric comorbidity or dual-eligible status were significantly less likely to initiate arformoterol, as compared to controls (all p <0.05). Conclusion: Medicare beneficiaries who initiated nebulized arformoterol therapy had more exacerbations and hospitalizations than controls 90 days prior to initiation. Findings revealed inadequate use of maintenance medications, suggesting a lack of compliance with evidence-based treatment guidelines.

Relationship of COPD Exacerbation Severity and Frequency on Risks for Future Events and Economic Burden in the Medicare Fee-For-Service Population

“… 8 In a study assessing medication management between 2010 and 2014 of the 100% Medicare FSS beneficiaries, Celli et al similarly reported inadequate use of maintenance medication. 31 Lack of optimal maintenance treatment contrary to guidelines can lead to worse outcomes. A study of patients with COPD using the HealthCore Integrated Research Database with enrollees from 14 commercial and Medicare Advantage health plans showed that compliance with the 2017 GOLD Report 32 were associated with less exacerbations and reduced COPD-related healthcare resource utilization and medical costs.…”

Trends, characteristics, in-hospital outcomes and mortality in surgical mitral valve replacement among patients with and without COPD in Spain (2001-2015)

“…However, we have followed similar designs of other descriptive studies on COPD hospitalizations [23–28]. Additionally, in several studies it has been assessed the validity of healthcare databases for COPD [29–34].…”

Yiqigubiao pill treatment regulates Sirtuin 5 expression and mitochondrial function in chronic obstructive pulmonary disease

“…These patients often experience symptoms such as dyspnea, fatigue, poor sleep, morning headaches, and energy loss, which reduce their quality of life and increase the medical burden ( 4 ). In fact, COPD affects 16 million people, with medical costs exceeding US $32.1 billion ( 5 ). A significant number of patients with COPD experience exacerbations that eventually lead to higher morbidity associated with such events ( 6 ).…”